Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Suspended 1Recruiting 1Active not recruiting 1

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 3Other hematologic neoplasm 2Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 9Myelodysplastic Syndromes 5Myeloproliferative Disorders 3Myelodysplastic-Myeloproliferative Diseases 2Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Myelomonocytic, Chronic 1Hodgkin Disease 1GATA2 Deficiency 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cytarabine 11fludarabine phosphate 8Peripheral Blood Stem Cell Transplantation 7Etoposide 7Filgrastim 6Daunorubicin 6Vorinostat 5Specimen Handling 5Decitabine 5Cyclophosphamide 5Busulfan 5Biopsy 5Methotrexate 4Cyclosporine 4venetoclax 3sargramostim 3decitabine and cedazuridine drug combination 3Liposomes 3Injections 3Idarubicin 3CPX-351 3Azacitidine 3tipifarnib 2romidepsin 2pomalidomide 2laromustine 2fludarabine 2Vincristine 2Tretinoin 2Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Myeloproliferative Disorders × decitabine and cedazuridine drug combination × Clear all
NCT05564390 2026-06-03

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT06661915 2026-05-29

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

National Cancer Institute (NCI)

Phase 2 Suspended
62 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT05600894 2026-05-13

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

National Cancer Institute (NCI)

Phase 2 Active not recruiting
132 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡